AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
PharmaCyte Biotech, Inc. Common Stock
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG001S69496
0.36▲ 0.01 (1.49%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
0.35
Day's Range
0.34 – 0.40
52-Week Range
0.33 – 1.51
Volume
44.7K
Avg Volume
289.7K
Share Statistics
Shares Outstanding
Employees
2
Exchange
XNAS
Listed
2003-09-11
Share count as of September 11, 2026

PharmaCyte Biotech, Inc. Common Stock (PMCB) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about PharmaCyte Biotech, Inc. Common Stock (PMCB)
What is PharmaCyte Biotech, Inc. Common Stock's Market Cap?
PharmaCyte Biotech, Inc. Common Stock's Market Cap is $3.8M, based on as-reported figures from SEC (XBRL) filings.
What is PharmaCyte Biotech, Inc. Common Stock's Enterprise Value?
PharmaCyte Biotech, Inc. Common Stock's Enterprise Value is -$14.0M, based on as-reported figures from SEC (XBRL) filings.
What is PharmaCyte Biotech, Inc. Common Stock's Revenue (TTM)?
PharmaCyte Biotech, Inc. Common Stock's Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is PharmaCyte Biotech, Inc. Common Stock's Net Income (TTM)?
PharmaCyte Biotech, Inc. Common Stock's Net Income (TTM) is -$16.1M, based on as-reported figures from SEC (XBRL) filings.
What is PharmaCyte Biotech, Inc. Common Stock's Diluted EPS (TTM)?
PharmaCyte Biotech, Inc. Common Stock's Diluted EPS (TTM) is -1.50, based on as-reported figures from SEC (XBRL) filings.
What is PharmaCyte Biotech, Inc. Common Stock's Net Debt?
PharmaCyte Biotech, Inc. Common Stock's Net Debt is -$17.8M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · PMCBAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJul 31, 2026Apr 30, 2026Jan 31, 2026Oct 31, 2025Jul 31, 2025Apr 30, 2025Jan 31, 2025Oct 31, 2024Jul 31, 2024Apr 30, 2024Jan 31, 2024Oct 31, 2023Jul 31, 2023Apr 30, 2023Jan 31, 2023Oct 31, 2022
Revenue
Operating expenses:
Research and Development Expense
Selling, General and Administrative Expense
Total operating expenses
Loss from operations
Other income (expense):
Interest Income
Net Interest Income———
Change in fair value of warrant liability
Change in fair value of derivative liability
Change in fair value of convertible note receivable – Femasys
Change in fair value of the convertible note receivable
Change in fair value of investment – QCLS
Change in fair value of warrant assets – QCLS
Gain on legal settlement – re-fair value of warrants
Non-Operating Income (Expense)
Total other income (expense), net
Income Tax Expense———
Net loss
Preferred stock dividends
Net loss attributable to common stockholders
Earnings Per Share (Basic)
Earnings Per Share (Diluted)